drugset / Trial / NCT06756152
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Phase 2/3
Recruiting
50 enrolled
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NaSingle-groupOpen-labelTreatment
Summary
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Timeline
- Start
- 2024-07-10
- Primary completion
- 2026-07-10
- Completion
- 2026-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Etoposide | Small molecule | 60 mg/kg | — |
| Background | Fludarabine | Small molecule | 150 mg/m2 | — |
| Background | Treosulfan | Small molecule | 42 g | — |